Dr. Salmon's research has focused on elucidating mechanisms of tissue injury in lupus and other autoimmune diseases. Her basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and end-organ damage in patients with lupus. She has identified new approaches to attenuate inflammation and tissue damage in models of lupus and rheumatoid arthritis. Ground-breaking laboratory discoveries about causes of pregnancy loss and preeclampsia, and subsequent observational studies in women with lupus and APS have allowed her to identify new targets to reduce damage and improve outcomes in patients with autoimmune illness.
Department of Medicine
Department of Medicine, Weill Cornell Medicine
Department of Obstetrics & Gynecology, Weill Cornell Medicine
Immunology & Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medicine
Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Collette Kean Research Chair, Hospital for Special Surgery
Senior Scientist, Hospital for Special Surgery
Attending Physician, Hospital for Special Surgery
Professor of Medicine, Weill Medical College of Cornell University (with tenure)
Associate Dean for Faculty Affairs, Weill Cornell Medicine
Professor, Graduate Program in Immunology and Microbial Pathogenesis, Weill Graduate School of Medical Sciences of Cornell University
Professor of Medicine in Obstetrics and Gynecology, Weill Cornell College of Medicine
Attending Physician, New York Presbyterian Hospital
Weill Cornell Medicine
Graduate School of Medical Sciences, Weill Cornell
American Board of Internal Medicine
Subspecialty of Rheumatology (ABIM)
Election to National Academy of Medicine
Election to Association of American Physicians
Lupus Insight Prize, Lupus Research Alliance
Master, American College of Rheumatology
Honorary member, European league Against Rheumatism
Evelyn V. Hess Research Award, Lupus Foundation of America
Virginia Kneeland Frantz '22 Distinguished Women in Medicine Award, Columbia P&S Alumni
Carol Nachman Prize, highest international award for rheumatology research
Theodore E. Woodward Award of the American Climatological Association
Dr. Edmond L. Dubois Memorial Lectureship Award, ACR
Alpha Omega Alpha, Columbia University
New York University, A.B.
Columbia University, College of Physicians and Surgeons , M.D. (Medical Scientist Training Program)
Resident in Medicine, The New York Hospital
Fellow in Rheumatic Diseases, Hospital for Special Surgery
The New York Hospital, New York, New York
Hospital for Special Surgery, Fellow in Rheumatic Diseases
Barbhaiya M, Salmon JE, Erkan D. Antiphospholipid Syndrome. in: Kelley's Textbook of Rheumatology, 11thth Edition, edited by GS Firestein, RA Budd, SE Gabriel, Koretsky G, IB McInnes, and JR O'Dell. Elsevier Saunders, Philadelphia, pp 1460-1472, 2021.
Salmon JE: Mechanisms of immune-mediated injury. in: Cecil Textbook of Medicine (26th edition), edited by L Goldman and AI Schafer, Elsevier, Philadelphia, pp 208-212, 2020.
Salmon JE, D'Agati V. Immunopathology of SLE. in: Rheumatology 7th Edition, edited by MC Hochberg, E Gravellese, AJ Silman, JS Smolen, ME Weinblatt, M Weisman. Elsevier, Philadelphia, pp 1127-1141, 2019.
Sammaritano LR, Salmon JE, Branch DW. Pregnancy and rheumatic diseases. in: Creasy and Resnik's Maternal-Fetal Medicine (8th edition), edited by R Resnik. MF Greene, CJ Lockwood, TR Moore, MF Greene, Joshua A. Copel, and RM Silver. Elsevier Saunders, Philadelphia, pp 1192-1207, 2019.
Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 64:307-24, 2013.
Burg N, Salmon JE, Hla T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheum 18:335-351, 2022.
Hong S, Banchereau R, Maslow BL, Guerra MM, Cardenas J, Baisch J, Branch DW, Porter TF, Sawitzke S, Laskin CA, Buyon JP, Merrill J, Sammaritano LR, Petri M, Gatewood E, Cepika A-M, Ohouo M, Obermoser G, Anguiano E, Kim TW, Nulsen J, Nehar-Belaid D, Blankenship D, Turner J, Banchereau J, Salmon JE*, Pascual V*. Longitudinal profiling of the human blood transcriptome in healthy and lupus pregnancy. (*equal contribution) J Exp Med 216: 1154-1169, 2019.
Qing X, Chinenov Y, Redecha P, Madaio M, Roelofs JJTH, Farber G, Issuree PD, Donlin L, Mcllwain DR, Mak TW, Blobel CP, Salmon JE. iRhom2 promotes lupus nephritis through TNF- and EGFR signaling. J Clin Invest 128:1397-1412, 2018.
Burg N, Swendeman S, Worgall S, Hla T, Salmon JE. Sphingosine-1 phosphate receptor-1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. Arthritis Rheum 70:1879-1888, 2018.
Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, Lockshin MD, Sammaritano LR, Merrill JT, Porter TF, Sawitzke A, Lynch AM, Buyon JP, Salmon JE. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or anti-phospholipid antibodies. Ann Rheum Dis 77:549-555, 2018.
Buyon JP, Kim YM, Guerra MM, Laskin CA, Petri M, Lockshin, MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E; Garabet L, Salmon JE. Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients. Ann Intern Med 163: 153-163, 2015
Issuree PDA, Maretzky T, McIlwain DR, Monette S, Qing X, Lang P, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, Yarilina A, Horiuchi K, Ivashkiv LB, Mak TW, Salmon JE*, Blobel CP*. IRHOM2 is a critical pathogenic mediator of inflammatory arthritis. (*equal contribution). J Clin Invest 123:928-32, 2013.
Girardi G, Redecha PB, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10: 1222-6, 2004.
Roman, MJ, Shanker B-A, Davis A, Lockshin M.D, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 349: 2399-406, 2003.
Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM and Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphosphospholipid syndrome. J Clin Invest 112: 1644-54, 2003.
For more publications, please see the PubMed listing.
Rheumatology Research Foundation Memorial Lecture
Lupus2020 meeting, Keynote Address
David Trentham Visiting Professorship at Beth Israel-Deaconess, Harvard Medicine
Lecturer at Scientific symposium to commemorate the 80-year anniversary of
King Gustaf V 80-year Foundation, Stockholm, Sweden
Department of Medicine Research Retreat Keynote Speaker, Medical College of Wisconsin
Mary Jane Keller Lectureship, Yale School of Medicine
Nanna Swartz Lectureship, Swedish Society of Medicine
Annual Ogryzlo Research Day Visiting Professor, University of Toronto
Kroc Lectureship, Washington University St. Louis
Dr. Edmond L. Dubois Memorial Lectureship Award, ACR
Soderberg Prize Symposium, Swedish Society of Medicine, Stockholm
The goal of Dr. Salmon's research is to identify predictors and determinants of disease phenotype in systemic lupus erythematosus (SLE) and related diseases, and to thereby identify targets for therapy. In SLE and other autoimmune diseases, autoantibodies and immune complexes initiate inflammation and organ damage through receptors for IgG and complement activation products. The laboratory investigates downstream mediators and effector mechanisms of tissue injury. Their basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and nephritis in patients with SLE. This work to define pathogenic mechanisms in SLE is likely to translate to non-autoimmune patients.
Dr. Salmon's laboratory defined structure-function relationships among human receptors for IgG, key effectors in immune complex diseases and showed that allelic variants were risk factors for nephritis. She led the first case-control study to define prevalence and clinical correlates of pre-clinical atherosclerosis in SLE and found accelerated and premature disease, independent of traditional cardiovascular risk factors, rather related to inflammation. The laboratory is currently pioneering efforts to target endothelial cells to limit immune complex-mediated injury in experimental models and translate their findings to patients.
Building on her discovery that innate immune pathways, complement, neutrophils and TNF-α, are critical effectors of pregnancy complications in mouse models, she led an NIH-funded, multi-center 11 year prospective longitudinal study of 700 pregnant patients to identify predictors of pregnancy outcomes in patients with lupus and/or anti-phospholipid syndrome. The laboratory is probing circulating biomarkers (angiogenic factors, transcriptome profiling, etc.) that are early predictors of poor pregnancy outcomes. In addition, they are using machine learning with large prospective lupus pregnancy cohorts to create a real-world algorithm to guide risk stratification. To directly apply her discoveries to patients, Dr. Salmon has embarked on the first interventional trial of biologic therapy to protect pregnancies at high risk for preeclampsia, an approach likely to have broad public health implications.
Effector mechanisms of immune-mediated injury
Modulators of inflammation
Role of vasculature in inflammation
Lupus and lupus nephritis
Pregnancy and preeclampsia
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Salmon as of February 01, 2021.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.